Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
Susan Bal(University of Alabama at Birmingham Hospital), Jesús G. Berdeja(Tennessee Oncology), Larry D. Anderson(Dana-Farber Cancer Institute), Kristen Hege(University of California, San Francisco), Tara Gregory(Colorado Blood Cancer Institute), Omar Nadeem(Harvard University), Mehmet H. Kocoglu(University of Maryland, Baltimore), Michael R. Burgess(Bristol-Myers Squibb (United States)), Myo Htut(City of Hope), Tonia J. Buchholz(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Yanping Chen(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Meng Li(Bristol-Myers Squibb (United States)), Allison Kaeding(Bristol-Myers Squibb (United States))
Cited by 39
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505